Introduction
The angiotensin receptor blockers (ARBs) are the most recent class of drug shown to be of benefit in patients with chronic heart failure (CHF), as recognised in the recent revision of the European Society of Cardiology (ESC) guidelines for the management of CHF. 1 The evidence base for these new recommendations mainly derives from the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) trial programme, the largest study to date in heart failure.
CHARM was designed as three, parallel, independent, integrated, randomised, double-blind, placebo-controlled clinical trials comparing candesartan with placebo in three distinct populations of CHF patients (Figure 1) . Two of these studies included patients with low left ventricular ejection fraction (LVEF < 40%). CHARM-Added 2 enrolled 2,548 patients with reduced LVEF who were symptomatic despite optimal therapy with an angiotensin-converting enzyme (ACE) inhibitor in addition to other heart failure treatment; CHARM-Alternative 3 enrolled 2,028 symptomatic patients with reduced LVEF who were not receiving an ACE inhibitor due to previous intolerance. Key patient characteristics at baseline in CHARM-Added and CHARM-Alternative are summarised in Table 1 .
Both CHARM-Added 2 and CHARM-Alternative 3 demonstrated significant morbidity and mortality benefits with candesartan in patients with CHF, reducing the primary composite endpoint of cardiovascular death and CHF hospitalisation. A preplanned pooled analysis of both studies reinforced this finding (hazard ratio [HR] 0.82, p<0.001) and also demonstrated a significant reduction in all-cause mortality in patients with low LVEF (HR 0.88, p=0.018). 4, 5 Perceived safety concerns may lead to reluctance to prescribe an ARB in patients with low LVEF, especially in those already treated with an ACE inhibitor. 1 Discussion of the efficacy and safety of candesartan in specific patient groups, based on the CHARM data, should overcome such perceptions. 
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Who Should Receive an ARB? Patients Intolerant to ACE Inhibitor Therapy
There is no doubt that treatment with an ARB is clearly indicated in patients with prior intolerance to ACE inhibitors, based on evidence from CHARM-Alternative. In that trial, treatment with candesartan led to a significant reduction in the primary outcome of cardiovascular death or CHF hospitalisation (by 23%, p=0.0004) ( Figure 2 ). 3 This effect was apparent early and was sustained throughout the study, emphasising the importance of early introduction of treatment in this patient group.
Baseline data indicated that the most common reasons for ACE inhibitor intolerance were cough and, to a lesser extent, symptomatic hypotension and renal dysfunction. 3 At the end of the study, the overall proportion of patients who permanently discontinued treatment due to adverse events or laboratory abnormalities was similar in the candesartan and placebo groups (21.5% vs. 19.3%, p=0.23). 3 Not unexpectedly for an agent that acts on the renin-angiotensin-aldosterone system (RAAS), patients were more likely to have permanently discontinued treatment with candesartan due to hypotension (3.7% vs. 0.9% with placebo, p<0.0001), renal dysfunction (6.1% vs.
2.7%, p<0.0001) and hyperkalaemia (1.9% vs. 0.3%, p=0.0005). 3 In particular, patients whose previous intolerance was due to renal dysfunction were more likely to have discontinued treatment (with either candesartan or placebo) due to increased creatinine (23.1% vs. 12.0% in the placebo group, p<0.0001) or increased potassium (13.6% vs 1.0%). 3 It is worth noting, however, that 75% of patients with pre-existing renal dysfunction continued on candesartan. There were no obvious differences in discontinuation due to cough (0.2% vs. 0.4%, p=0.69) or angioedema (0.1% vs. 0%, p=0.50), 3 suggesting that these adverse effects are not caused by ARBs ( Figure  3 ).
Thus, data from CHARM-Alternative support the efficacy and safety of candesartan in heart failure patients who are intolerant to an ACE inhibitor. The clearest indication for the use of candesartan is in those patients intolerant to an ACE inhibitor due to cough or angioedema. Careful monitoring is recommended in patients intolerant to an ACE inhibitor due to hypotension, hyperkalaemia or renal dysfunction. 
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Patients who Remain Symptomatic Despite Optimal Therapy
There has previously been reluctance to add an ARB to the treatment regimen of symptomatic patients who are already receiving an ACE inhibitor and a beta-blocker, largely attributable to findings from the Valsartan Heart Failure Trial (Val-HeFT). 6 In that trial, treatment with valsartan (160 mg twice daily) in addition to conventional CHF therapy significantly reduced the risk of the composite endpoint of death and cardiovascular morbidity (admission to hospital for CHF, ≥ four hours' intravenous treatment for CHF without admission, or cardiac arrest with resuscitation) by 13.2% compared with placebo, mainly driven by a 27.5% reduction in the risk of hospital admission for CHF. 6 However, subsequent analyses suggested that patients treated with an ACE inhibitor and a beta-blocker at baseline actually fared worse when valsartan was introduced. 6 Findings from CHARM-Added effectively counter these concerns. Treatment with candesartan in patients remaining symptomatic despite optimal therapy (all received an ACE inhibitor and 55% also received a beta-blocker) ( Table 1) , significantly reduced the primary composite endpoint of cardiovascular death or hospitalisation for worsening CHF by 15% (p=0.011) ( Figure 4) , and cardiovascular death alone by 16% (p=0.029). 2 As in CHARM-Alternative, 3 these effects were rapid in onset and striking after one year follow-up. Additionally, a significantly higher proportion of patients showed improvement in New York Heart Association (NYHA) functional class on candesartan compared with placebo (p=0.003). 7 These data from CHARM were largely responsible for recognition of the important role of ARBs in the management of CHF patients who remain symptomatic despite conventional therapy including an ACE inhibitor, as detailed in the updated guidelines. 1 CHARM-Added also showed that the efficacy of candesartan was not influenced by baseline use of a beta-blocker in addition to an ACE inhibitor.
Patients on 'triple therapy' (i.e. ACE inhibitor, betablocker and candesartan) showed similar incremental reductions in cardiovascular death and CHF hospitalisation to patients who were not taking a beta-blocker at baseline. 2 Among patients who were taking both an ACE inhibitor and betablocker at baseline, cardiovascular death occurred in 25% of patients on candesartan compared with 27% in the placebo group (p=0.22); by comparison, in patients who were not taking a betablocker at baseline, cardiovascular death rates were 35% and 39%, respectively (p=0.20). 2 Safety concerns have been raised about patients receiving a high dose of an ACE inhibitor in addition to an ARB. However, data from CHARM-Added showed that candesartan was as effective in patients taking a recommended dose of an ACE inhibitor as in those patients taking a lower dose. 2 Moreover, subsequent analysis of the CHARM-Added database showed that the benefits of candesartan were preserved even in patients on high doses of ACE inhibitor, with or without a beta-blocker.
Special Subgroups
Pooled analyses of data from CHARM in patients with reduced LVEF clearly demonstrated that the morbidity and mortality benefits of candesartan therapy were consistent across a wide range of patient subgroups. 4, 5 Candesartan was as effective in younger (< 65 years) as in older patients (≥ 75 years), was effective in male and female patients and there was no evidence that ethnic origin influenced response to treatment response. 4 Moreover, the efficacy of candesartan was consistent irrespective of whether patients received beta-blockers, ACE inhibitors or an aldosterone antagonist. 4 Currently, there are only limited data relating to the safety and efficacy of the combination of an ARB, ACE inhibitor, beta-blocker and spironolac- 
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Permanent study drug discontinuation in the CHARM-Alternative trial, 3 tone. Data from CHARM-Added 2 suggest a consistent effect of candesartan on the primary endpoint in patients receiving all four treatments, although this is not statistically significant since the patient numbers are small (only 17% of patients received spironolactone) and the confidence intervals correspondingly wide. Given the current evidence base, the use of an ARB is not routinely recommended in such patients, except in special circumstances. 8
When Should Treatment be Initiated?
Data from CHARM-Alternative 3 and CHARM-Added 2 showed that there was a rapid onset of effect with candesartan, which was sustained throughout both studies (Figures 2 and 4 ). This effect was most evident for reduction in CHF hospitalisation, which is associated with substantial patient morbidity and represents an economic burden for healthcare systems. The data emphasise the importance of early initiation of candesartan after optimising treatment with an ACE inhibitor and beta-blocker. If patients cannot tolerate an ACE inhibitor, candesartan should be started as soon as possible.
How Should Treatment be Given?
Practical guidance for the use of candesartan is based on the titration schedule used in the CHARM programme. Treatment should be initiated at a low dose (4 mg once daily), and doubled as tolerated at a minimum of fortnightly intervals to a target dose of 32 mg once daily (or the highest tolerated dose). Combined data from CHARM-Added and CHARM-Alternative showed that 60% of patients in the candesartan group achieved this target dose at the end of the six-month study. 4 Extensive safety analyses indicate that candesartan is generally well tolerated in patients who have heart failure with low LVEF. In CHARM, the benefits of candesartan were achieved with a low incidence of adverse effects, characteristic of drugs that inhibit the RAAS. Routine monitoring of blood pressure, and serum creatinine and potassium, is warranted, particularly in patients who were previously intolerant to an ACE inhibitor due to hypotension or renal dysfunction (Figure 3 ).
In patients receiving candesartan in addition to an ACE inhibitor (with or without a beta-blocker), data from CHARM-Added 2 indicate that certain baseline characteristics may predispose to an increased risk for adverse effects. Discontinuation due to hypotension was most likely in patients with low pre-treatment systolic blood pressure (< 100 mmHg), discontinuation due to renal dysfunction was most likely in patients with elevated serum creatinine at baseline, and discontinuation due to hyperkalaemia was more likely in elderly patients (≥ 75 years) or in patients with diabetes or elevated serum creatinine or potassium at baseline. Thus, the clinical skills and judgement of the clinician are integral to the routine monitoring of patients.
Detailed guidance on the use of ARBs and other drugs for heart failure has recently been published. 8
Conclusion
The CHARM study clearly demonstrated that treatment with candesartan has significant morbidity and mortality benefits in CHF patients with low LVEF. Moreover, extensive safety analyses have indicated that candesartan was well tolerated when administered to patients receiving an ACE inhibitor (even at maximal doses) and beta-blocker, as well as in patients previously intolerant to an ACE inhibitor. These findings emphasise the importance of candesartan in achieving substantial clinical improvement in CHF patients with reduced LVEF, as has been recognised in recently published ESC guidelines for the management of CHF. 
